KBC Group NV Has $121.11 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

KBC Group NV lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 68.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 616,299 shares of the medical research company’s stock after buying an additional 250,458 shares during the period. KBC Group NV owned about 0.34% of IQVIA worth $121,109,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of IQV. FMR LLC increased its position in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in IQVIA during the third quarter worth $147,683,000. JPMorgan Chase & Co. raised its position in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Nordea Investment Management AB lifted its stake in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, Mizuho Securities USA LLC grew its position in shares of IQVIA by 1,397.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 210,428 shares of the medical research company’s stock valued at $49,865,000 after acquiring an additional 196,380 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on IQV shares. Barclays cut their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Redburn Atlantic began coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 target price for the company. Robert W. Baird lowered their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Finally, TD Cowen decreased their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Trading Down 0.7 %

Shares of NYSE IQV opened at $204.54 on Monday. The firm has a 50 day moving average price of $199.71 and a two-hundred day moving average price of $221.11. The stock has a market cap of $37.12 billion, a P/E ratio of 26.84, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.